Microglial Metabolic Reprogramming is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Microglial metabolic reprogramming refers to the dynamic shifts in cellular energy metabolism that [microglia[/cell-types/microglia [2].
In the healthy brain, surveilling [microglia[/cell-types/microglia:89. https://doi.org/10.1186/s12974-022-02456-2" title="Huang Y, et al. Metabolic reprogramming in [microglia[/entities/microglia from Alzheimer's Disease brain. J neuroinflammation. 2022;19(1):89. ]]https://doi.org/10.1186/s12974-022-02456-2">[3].)
Upon disease-related activation, microglia shift toward aerobic glycolysis:
- Enhanced glucose uptake: Upregulation of glucose transporters (GLUT1/SLC2A1) increases glucose import 3-5 fold
- Elevated glycolytic enzymes: Hexokinase 2 (HK2), phosphofructokinase (PFK), and pyruvate kinase M2 (PKM2) are strongly upregulated
- Lactate production: Pyruvate is converted to lactate by LDH-A rather than entering the TCA cycle
- Pentose phosphate pathway: Increased flux through PPP generates NADPH for [ROS[/mechanisms/oxidative-stress production and nucleotide biosynthesis
- Mitochondrial dysfunction: Progressive loss of mitochondrial membrane potential, reduced OXPHOS complex activity
- Pro-inflammatory phenotype: Glycolytic metabolism sustains [NLRP3 inflammasome[/mechanisms/nlrp3-inflammasome activation and cytokine production
In chronic neurodegeneration, sustained glycolytic activation leads to metabolic exhaustion:
- Energy crisis: Both OXPHOS and glycolysis become impaired, leading to ATP depletion
- Impaired phagocytosis: Loss of energy supply prevents effective clearance of amyloid plaques and debris
- Senescent phenotype: Metabolically exhausted microglia resemble [senescent cells], with irreversible pro-inflammatory features
- Lipid accumulation: Failure of fatty acid oxidation drives [lipid droplet accumulation], producing the LDAM phenotype
The mechanistic target of rapamycin ([mTOR[/mechanisms/mtor-neurodegeneration is a central metabolic sensor that drives the glycolytic switch in microglia:
- [TREM2[/genes/trem2-[mTOR[/mechanisms/mtor-neurodegeneration coupling: [TREM2[/proteins/trem2 ligation by lipoproteins and [amyloid-beta[/entities/amyloid-beta activates PI3K-AKT-[mTOR[/mechanisms/mtor-neurodegeneration signaling, increasing microglial metabolic capacity. [TREM2[/genes/trem2 loss-of-function variants (R47H, R62H) — which are Alzheimer's Disease risk factors — impair [mTOR[/mechanisms/mtor-neurodegeneration activation, reducing both glycolytic and OXPHOS capacity and trapping microglia in a metabolically dysfunctional state Ulland et al., 2017
- HIF-1α stabilization: [mTOR[/mechanisms/mtor-neurodegeneration activates hypoxia-inducible factor 1-alpha (HIF-1α), the master transcriptional regulator of glycolytic gene expression. HIF-1α upregulates GLUT1, HK2, LDHA, and PDK1 (which blocks pyruvate entry into mitochondria)
- Rapamycin effects: [mTOR[/mechanisms/mtor-neurodegeneration inhibition by rapamycin reduces microglial glycolysis and inflammatory cytokine production, but also impairs beneficial [TREM2[/genes/trem2-dependent responses, highlighting the dual nature of [mTOR[/entities/mtor in neurodegeneration
AMP-activated protein kinase (AMPK) is the counterregulator of mTOR and promotes OXPHOS:
- Energy sensing: AMPK is activated by high AMP/ATP ratio, sensing energy depletion
- OXPHOS promotion: AMPK activates PGC-1α, promoting mitochondrial biogenesis and fatty acid oxidation
- Anti-inflammatory effects: AMPK activation suppresses [NF-kappa-B] signaling, reducing pro-inflammatory cytokine production
- Therapeutic potential: AMPK activators (metformin, AICAR) can restore microglial OXPHOS and reduce neuroinflammation in preclinical models
Several glycolytic enzymes have moonlighting functions that directly regulate microglial inflammatory responses:
- PKM2 (pyruvate kinase M2): In its dimeric form, PKM2 translocates to the nucleus and acts as a transcriptional coactivator for HIF-1α and STAT3, amplifying inflammatory gene expression. Pharmacological stabilization of PKM2 tetramers (using TEPP-46 or DASA-58) traps PKM2 in its enzymatic form, preventing nuclear translocation and reducing inflammation Palsson-McDermott et al., 2015
- HK2 (hexokinase 2): Beyond its glycolytic role, HK2 interacts with VDAC on the mitochondrial outer membrane, regulating [NLRP3[/mechanisms/nlrp3-inflammasome inflammasome activation
- GAPDH: Undergoes post-translational modifications (succination, oxidation) in inflammatory microglia, affecting both glycolytic flux and gene regulation
¶ Itaconate and the TCA Cycle
The TCA cycle intermediate itaconate has emerged as a key immunometabolite in microglia:
- Immune-responsive gene 1 (IRG1/ACOD1): Produces itaconate from cis-aconitate in the TCA cycle
- Anti-inflammatory effects: Itaconate inhibits succinate dehydrogenase (SDH), reducing succinate accumulation and HIF-1α stabilization
- Nrf2 activation: Dimethyl itaconate activates the [Nrf2[/genes/nrf2 antioxidant pathway, reducing oxidative damage
- Therapeutic potential: Itaconate derivatives are being explored as anti-inflammatory therapeutics for neurodegeneration
In [Alzheimer's disease[/diseases/alzheimers, microglial metabolic reprogramming occurs in stages:
- Early activation: [Aβ[/entities/amyloid-beta oligomers trigger [TREM2[/genes/trem2-mTOR-dependent glycolytic switch, initially enhancing microglial motility and phagocytosis — this may represent a protective response
- Chronic glycolysis: Sustained [Aβ[/entities/amyloid-beta exposure locks microglia in a glycolytic state with impaired OXPHOS. [Disease-associated microglia (DAM) show elevated HK2, PKM2, and LDHA expression
- Metabolic exhaustion: In advanced disease, microglia surrounding dense-core plaques show both impaired glycolysis and OXPHOS, becoming metabolically inert and unable to restrict plaque growth
- Spatial metabolic heterogeneity: Recent spatial transcriptomics studies reveal that microglial metabolic state varies with distance from amyloid plaques — plaque-proximal microglia are most glycolytic, while those further away maintain more homeostatic metabolism Xu et al., 2025
In [Parkinson's disease[/diseases/parkinsons:
- [alpha-synuclein/proteins/alpha fibrils activate microglial TLR2/4 signaling, triggering [NF-κB[/entities/nf-kb-dependent glycolytic reprogramming
- [LRRK2/proteins/lrrk2 mutations (G2019S) alter mitochondrial fission/fusion dynamics in microglia, impairing OXPHOS and driving compensatory glycolysis
- [GBA[/genes/gba mutations disrupt lysosomal-mitochondrial lipid trafficking, creating metabolic stress that promotes glycolytic shift
- [dopamine[/entities/dopamine depletion in the [substantia nigra[/brain-regions/substantia-nigra removes tonic inhibition of microglial activation, permitting metabolic reprogramming
In [ALS[/diseases/als:
- [SOD1/proteins/sod1 mutant protein in microglia induces [mitochondrial dysfunction[/mechanisms/mitochondrial-dysfunction and oxidative damage, forcing glycolytic dependence
- [TDP-43[/entities/tdp-43 pathology disrupts RNA processing of metabolic enzyme transcripts, altering the metabolic transcriptome
- Spinal cord microglia show progressive metabolic decline paralleling [motor neuron/cell-types/motor-[neurons[/entities/neurons degeneration
Several therapeutic approaches target microglial metabolism:
- mTOR modulators: Rapamycin and its analogs reduce glycolytic inflammation but must be carefully dosed to preserve beneficial [TREM2[/genes/trem2-mTOR signaling
- AMPK activators: Metformin, AICAR, and the natural compound berberine promote OXPHOS and reduce neuroinflammation
- HIF-1α inhibitors: Pharmacological inhibition of HIF-1α (using echinomycin, acriflavine) reduces glycolytic gene expression in activated microglia
- PKM2 stabilizers: TEPP-46 and DASA-58 prevent nuclear PKM2 activity, reducing inflammatory gene transcription
- Itaconate derivatives: 4-octyl itaconate and dimethyl itaconate activate anti-inflammatory pathways
- NAD+ precursors: Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) restore mitochondrial function by replenishing [NAD+ pools]
- MitoQ and MitoTEMPO: Mitochondria-targeted antioxidants that reduce mitochondrial [ROS[/mechanisms/oxidative-stress and preserve OXPHOS capacity
- Urolithin A: Activates [mitophagy[/mechanisms/mitophagy, clearing damaged mitochondria and promoting biogenesis of healthy organelles
- SS-31 (elamipretide): Stabilizes cardiolipin in the inner mitochondrial membrane, supporting electron transport chain function
¶ Ketogenic and Dietary Approaches
- Ketone bodies: β-hydroxybutyrate (BHB) can serve as alternative fuel for microglial OXPHOS, bypassing glycolytic impairment. BHB also inhibits [NLRP3[/mechanisms/nlrp3-inflammasome inflammasome activation
- Ketogenic diet: Preclinical studies show reduced neuroinflammation and improved microglial function in AD models fed ketogenic diets
- Intermittent fasting: Enhances AMPK activation and mitophagy, potentially restoring microglial metabolic health
The study of Microglial Metabolic Reprogramming has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ Replication and Evidence
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
-
- [microglia[/cell-types/microglia/cell-types/microglia
-
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
1 references |
| Replication |
100% |
| Effect Sizes |
50% |
| Contradicting Evidence |
100% |
| Mechanistic Completeness |
50% |
Overall Confidence: 54%